BLA 761416 · Jazz Pharms
Ziihera
Zanidatamab-Hrii · Injection · Bispecific HER2-directed Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Nov 20, 2024: To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 20, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
34
6 Phase 3, 16 recruiting
FAERS reports
82
37 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIARRHEA AND EMBRYO-FETAL TOXICITY ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life threatening and fatal cases. Use antidiarrheal prophylaxis during the first cycle when ZIIHERA is given in combination with these drugs. Manage with antidiarrheals and supportive measures as clinically indicated. Interrupt, reduce the dose or discontinue ZIIHERA based on severity [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.5 )] . Embryo-Fetal Toxicity: Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.1 , 8.3 )] . WARNING: DIARRHEA and EMBRYO‑FETAL TOXICITY See full...
What it is approved for
From the label in effect Aug 24, 2026.
ZIIHERA is a bispecific HER2-directed antibody indicated for: Gastroesophageal Adenocarcinoma (GEA) • in combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab-jsgr, as first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test. ( 1.1 ) • in combination with fluoropyrimidine- and platinum-containing chemotherapy, as first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test. ( 1.1 ) Biliary Tract Cancer (BTC) • for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-authorized test.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 ) 1.1 Gastroesophageal Adenocarcinoma (GEA) • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] . • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with...
Mechanism: Zanidatamab-hrii is a bispecific HER2-directed antibody that binds to extracellular domains 2 (ECD2) and 4 (ECD4) on HER2. Similar to other HER2-directed antibodies, in vitro binding of zanidatamab-hrii with HER2 causes clustering and results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2026 Supplement 2 · Efficacy · priority review OrphanLetterLabel
- Nov 20, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- ZIIHERA · ZANIDATAMAB-HRII 300MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zanidatamab" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerPivotal-lookingNot yet recruiting
UNICANCERAcademic, hospital or other
NCT07745296 · 990 participants (planned) · Start Jan 2, 2027 · Primary completion Jul 2, 2033
Drug: Futibatinib; Ivosidenib + Capecitabine and 2 more · For: Biliary Tract Cancer (BTC)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPivotal-lookingActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05152147 · 920 participants · Start Dec 2, 2021 · Primary completion Jul 15, 2026
Drug: Zanidatamab; Tislelizumab and 5 more · For: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Pergamino, Argentina · 227 sites in all
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06324357 · 910 participants (planned) · Start Jun 28, 2024 · Primary completion Jan 8, 2029
Drug: Zongertinib; Trastuzumab deruxtecan and 6 more · For: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 2 more
Sites: Cerritos, California; Los Angeles, California; Orange, California · 105 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT06435429 · 550 participants (planned) · Start Aug 13, 2024 · Primary completion Apr 28, 2028
Drug: Zanidatamab; Trastuzumab and 4 more · For: Metastatic HER2-positive Breast Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Cerritos, California · 166 sites in all
Iambic Therapeutics, IncIndustry
NCT06253871 · 463 participants (planned) · Start Mar 25, 2024 · Primary completion Oct 2028
Drug: IAM1363; Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab and 3 more · For: HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer and 10 more
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 53 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use23
- infusion related reaction11
- diarrhoea10
- chills9
- pyrexia6
- ejection fraction decreased4
- hyperpyrexia3
- acute kidney injury2
- arthralgia2
- disease progression2
- drug ineffective2
- gastrointestinal haemorrhage2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 35 |
| 2026 | 47 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Shitara K, Elimova E, Liu T, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, et al. · Lancet Oncol 2023 · Clinical Trial, Phase II, Multicenter Study
- Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, et al. · Cancer Discov 2024 · Research Support, Non-U.S. Gov't, Clinical Trial, Phase I
- Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Meric-Bernstam F, Beeram M, Hamilton E, et al. · Lancet Oncol 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M, Chui MH, Zhou Q, et al. · Gynecol Oncol 2024 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study.
Wang X, Lee KS, Zeng X, et al. · ESMO Open 2025 · Multicenter Study, Clinical Trial, Phase II
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.